Dendreon Corporation (NASDAQ: DNDN) has appointed Hans Bishop as Chief Operating Officer. Mr. Bishop will assume the position on January 4, 2010. Prior to this position, he served as President of Specialty Medicine Business as Bayer. He also served as an executive VP at Bayer HealthCare LLC. Mr. Bishop will be responsible for preparing for and leading the commercial launch of PROVENGE. He graduated from Brunel University in London with a BS in chemistry.
MicroCap Insider is a web-based financial portal that publishes a free penny stock newsletter providing stock alerts on companies positioned to deliver high-yield gains to investors. Sign Up for our Free Stock Newsletter
About Dendreon
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce ACI product candidates designed to stimulate an immune response.
Investors interested in receiving small cap stock alerts through the penny stock newsletter published by MicroCap Insider can sign up for free by visiting our website
About Us
MicroCap Insider is a leading penny stock web site with extensive experience in the OTC market, providing top stock picks, investing tips and exclusive research on small cap stocks on the verge of producing large financial gains.
Please click here to read the full disclaimer
